Sequence variability of HCV Core region: Important predictors of HCV induced pathogenesis and viral production

Infection, Genetics and Evolution

Volumn 11, Issue 3, 2011, Pages 543-556

  Khaliq, Saba ^a   Jahan, Shah ^a   Pervaiz, Asim ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

Amino acid substitutions; Genetic diversity; HCV Core; Interferon therapy

Indexed keywords

CORE PROTEIN; FAT DROPLET; HEPATITIS C VIRUS CORE PROTEIN; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; CELL CYCLE PHASE; CYTOKINE RESPONSE; DOSE RESPONSE; FATTY LIVER; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; VIRUS ASSEMBLY; VIRUS CARCINOGENESIS; VIRUS CORE; VIRUS IDENTIFICATION; VIRUS MUTATION;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DRUG THERAPY, COMBINATION; FATTY LIVER; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERONS; LIVER NEOPLASMS; RIBAVIRIN; VIRAL CORE PROTEINS; VIRUS REPLICATION;

FLAVIVIRIDAE; HEPATITIS C VIRUS; RNA VIRUSES;

EID: 79953105820     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.01.017     Document Type: Review

References (223)

1. Abid K., Pazienza V., de G.A., Rubbia-Brandt L., Conne B., Pugnale P., Rossi C., Mangia A., Negro F. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J. Hepatol. 2005, 42:744-751.
2. Adinolfi L.E., Gambardella M., Andreana A., Tripodi M.F., Utili R., Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358-1364.
3. Ai L.S., Lee Y.W., Chen S.S. Characterization of hepatitis C virus core protein multimerization and membrane envelopment: revelation of a cascade of core-membrane interactions. J. Virol. 2009, 83:9923-9939.
4. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Chayama K., Nakamura Y., Kumada H. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52:421-429.
5. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Kumada H. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J. Med. Virol. 2009, 81:452-458.
6. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Kumada H. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J. Med. Virol. 2009, 81:1032-1039.
7. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Kumada H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology 2009, 52:301-309.
8. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Chayama K., Nakamura Y., Kumada H. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J. Med. Virol. 2010, 82:575-582.
9. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Kumada H. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007, 46:1357-1364.
10. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Kumada H. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol. 2007, 46:403-410.
11. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Kumada H. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J. Med. Virol. 2007, 79:1686-1695.
12. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Kumada H. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J. Med. Virol. 2008, 80:1363-1369.
13. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Miyakawa Y., Kumada H. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007, 50:361-368.
14. Akuta N., Suzuki F., Sezaki H., Suzuki Y., Hosaka T., Someya T., Kobayashi M., Saitoh S., Watahiki S., Sato J., Kobayashi M., Arase Y., Ikeda K., Kumada H. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J. Med. Virol. 2006, 78:83-90.
15. Akuta N., Suzuki F., Sezaki H., Suzuki Y., Hosaka T., Someya T., Kobayashi M., Saitoh S., Watahiki S., Sato J., Matsuda M., Kobayashi M., Arase Y., Ikeda K., Kumada H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48:372-380.
16. Alam S.S., Nakamura T., Naganuma A., Nozaki A., Nouso K., Shimomura H., Kato N. Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: the core protein-encoding region. Acta Med. Okayama 2002, 56:141-147.
17. Alberti A., Chemello L., Benvegnu L. Natural history of hepatitis C. J. Hepatol. 1999, 31(Suppl. 1):17-24.
18. Allison M.E., Wreghitt T., Palmer C.R., Alexander G.J. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J. Hepatol. 1994, 21:1135-1139.
19. Alsaleh K., Delavalle P.Y., Pillez A., Duverlie G., Descamps V., Rouille Y., Dubuisson J., Wychowski C. Identification of basic amino acids at the N-terminal end of the core protein crucial for HCV infectivity. J. Virol. 2010, 84:12515-12528.
20. Andre P., Perlemuter G., Budkowska A., Brechot C., Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin. Liver Dis. 2005, 25:93-104.
21. Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari S.M., Goglia F., Ferrannini E. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 2005, 28:2548-2550.
22. Banerjee S., Saito K., it-Goughoulte M., Meyer K., Ray R.B., Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J. Virol. 2008, 82:2606-2612.
23. Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., Rothman P.B. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J. Clin. Invest. 2005, 115:2462-2471.
24. Barba G., Harper F., Harada T., Kohara M., Goulinet S., Matsuura Y., Eder G., Schaff Z., Chapman M.J., Miyamura T., Brechot C. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1200-1205.
25. Bartenschlager R., hlborn-Laake L., Mous J., Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 1993, 67:3835-3844.
26. Bartenschlager R., hlborn-Laake L., Mous J., Jacobsen H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 1994, 68:5045-5055.
27. Baumert T.F., Ito S., Wong D.T., Liang T.J. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 1998, 72:3827-3836.
28. Blanchard E., Hourioux C., Brand D., it-Goughoulte M., Moreau A., Trassard S., Sizaret P.Y., Dubois F., Roingeard P. Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111. J. Virol. 2003, 77:10131-10138.
29. Blindenbacher A., Duong F.H., Hunziker L., Stutvoet S.T., Wang X., Terracciano L., Moradpour D., Blum H.E., Alonzi T., Tripodi M., La M.N., Heim M.H. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003, 124:1465-1475.
30. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., Heinrich P.C., Haussinger D. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003, 17:488-490.
31. Boulant S., Douglas M.W., Moody L., Budkowska A., Targett-Adams P., McLauchlan J. Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic 2008, 9:1268-1282.
32. Boulant S., Montserret R., Hope R.G., Ratinier M., Targett-Adams P., Lavergne J.P., Penin F., McLauchlan J. Structural determinants that target the hepatitis C virus core protein to lipid droplets. J. Biol. Chem. 2006, 281:22236-22247.
33. Boulant S., Targett-Adams P., McLauchlan J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J. Gen. Virol. 2007, 88:2204-2213.
34. Boulant S., Vanbelle C., Ebel C., Penin F., Lavergne J.P. Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. J. Virol. 2005, 79:11353-11365.
35. Brown R.A., Gralewski J.H., Eid A.J., Knoll B.M., Finberg R.W., Razonable R.R. R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. Transplantation 2010, 89:811-815.
36. Bukh J., Miller R.H., Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 1995, 15:41-63.
37. Camma, C., Bruno, S., Di, M., V, Di, B.D., Rumi, M., Vinci, M., Rebucci, C., Cividini, A., Pizzolanti, G., Minola, E., Mondelli, M.U., Colombo, M., Pinzello, G., Craxi, A., 2006. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43, 64-71.
38. Caronia S., Taylor K., Pagliaro L., Carr C., Palazzo U., Petrik J., O'Rahilly S., Shore S., Tom B.D., Alexander G.J. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 30:1059-1063.
39. Chen X., Bhandari R., Vinkemeier U., Van Den A.F., Darnell J.E., Kuriyan J. A reinterpretation of the dimerization interface of the N-terminal domains of STATs. Protein Sci. 2003, 12:361-365.
40. Cho J.W., Baek W.K., Suh S.I., Yang S.H., Chang J., Sung Y.C., Suh M.H. Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels. Liver 2001, 21:137-142.
41. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
42. Choo Q.L., Richman K.H., Han J.H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P.J. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2451-2455.
43. Ciccaglione A.R., Stellacci E., Marcantonio C., Muto V., Equestre M., Marsili G., Rapicetta M., Battistini A. Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J. Virol. 2007, 81:202-214.
44. Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afdhal N., Brown R.S., Belle S.H., Hoofnagle J.H., Kleiner D.E., Howell C.D. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
45. Conjeevaram H.S., Kleiner D.E., Everhart J.E., Hoofnagle J.H., Zacks S., Afdhal N.H., Wahed A.S. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007, 45:80-87.
46. Costa-Rivero N., Musacchio A., Lorenzo L., Alvarez C., Morales J. Processing of the Hepatitis C virus precursor protein expressed in the methylotrophic yeast Pichia pastoris. Biochem. Biophys. Res. Commun. 2002, 295:81-84.
47. Davis G.L. Hepatitis C virus genotypes and quasispecies. Am. J. Med. 1999, 107:21S-26S.
48. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
49. De Mitri M.S., Mele L., Chen C.H., Piccinini A., Chianese R., D'Errico A., Alberti A., Pisi E. Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma. J. Hepatol. 1998, 29:887-892.
50. De F.R., Steinkuhler C. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr. Top. Microbiol. Immunol. 2000, 242:149-169.
51. de G.A., Pazienza V., Pugnale P., Bruttin F., Rubbia-Brandt L., Juge-Aubry C.E., Meier C.A., Hadengue A., Negro F. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment. Pharmacol. Ther. 2006, 23:107-114.
52. Domanski P., Witte M., Kellum M., Rubinstein M., Hackett R., Pitha P., Colamonici O.R. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J. Biol. Chem. 1995, 270:21606-21611.
53. Donlin M.J., Cannon N.A., Aurora R., Li J., Wahed A.S., Di Bisceglie A.M., Tavis J.E. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 2010, 5:e9032.
54. Donlin M.J., Cannon N.A., Yao E., Li J., Wahed A., Taylor M.W., Belle S.H., Di Bisceglie A.M., Aurora R., Tavis J.E. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J. Virol. 2007, 81:8211-8224.
55. El-Serag H.B., Richardson P.A., Everhart J.E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am. J. Gastroenterol. 2001, 96:2462-2467.
56. Enomoto N., Maekawa S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 2010, 53:66-69.
57. Erhardt A., Hassan M., Heintges T., Haussinger D. Hepatitis C virus core protein induces cell proliferation and activates ERK JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology 2002, 292:272-284.
58. Fartoux L., Poujol-Robert A., Guechot J., Wendum D., Poupon R., Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005, 54:1003-1008.
59. Feinstone S.M., Kapikian A.Z., Purcell R.H., Alter H.J., Holland P.V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 1975, 292:767-770.
60. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Chaneac M., Reddy K.R. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol. 2005, 43:425-433.
61. Fishman S.L., Factor S.H., Balestrieri C., Fan X., Dibisceglie A.M., Desai S.M., Benson G., Branch A.D. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:3205-3213.
62. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
63. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
64. Fukasawa M., Tanaka Y., Sato S., Ono Y., Nitahara-Kasahara Y., Suzuki T., Miyamura T., Hanada K., Nishijima M. Enhancement of de novo fatty acid biosynthesis in hepatic cell line Huh7 expressing hepatitis C virus core protein. Biol. Pharm. Bull. 2006, 29:1958-1961.
65. Fukuhara T., Takeishi K., Toshima T., Morita K., Ueda S., Iguchi T., Nagata S., Sugimachi K., Ikegami T., Gion T., Soejima Y., Taketomi A., Maehara Y. Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis. Hepatol. Res. 2010, 40:171-178.
66. Fukutomi T., Zhou Y., Kawai S., Eguchi H., Wands J.R., Li J. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005, 41:1096-1105.
67. Gale M., Blakely C.M., Kwieciszewski B., Tan S.L., Dossett M., Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell Biol. 1998, 18:5208-5218.
68. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
69. Giannini C., Brechot C. Hepatitis C virus biology. Cell Death Differ. 2003, 10(Suppl. 1):S27-S38.
70. Gomez J., Martell M., Quer J., Cabot B., Esteban J.I. Hepatitis C viral quasispecies. J. Viral Hepat. 1999, 6:3-16.
71. Gonzalez-Peralta R.P., Davis G.L., Lau J.Y. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J. Hepatol. 1994, 21:255-259.
72. Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 1993, 67:1385-1395.
73. Gretch D.R., Polyak S.J., Wilson J.J., Carithers R.L., Perkins J.D., Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J. Virol. 1996, 70:7622-7631.
74. Hayashi K., Katano Y., Ishigami M., Itoh A., Hirooka Y., Nakano I., Urano F., Yoshioka K., Toyoda H., Kumada T., Goto H. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. J. Viral Hepat. 2010, [Epub ahead of print].
75. Heimann M., Roman-Sosa G., Martoglio B., Thiel H.J., Rumenapf T. Core protein of pestiviruses is processed at the C terminus by signal peptide peptidase. J. Virol. 2006, 80:1915-1921.
76. Herzer K., Weyer S., Krammer P.H., Galle P.R., Hofmann T.G. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res. 2005, 65:10830-10837.
77. Hezode C., Lonjon I., Roudot-Thoraval F., Pawlotsky J.M., Zafrani E.S., Dhumeaux D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment. Pharmacol. Ther. 2003, 17:1031-1037.
78. Hezode C., Roudot-Thoraval F., Zafrani E.S., Dhumeaux D., Pawlotsky J.M. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J. Viral Hepat. 2004, 11:455-458.
79. Hijikata M., Kato N., Ootsuyama Y., Nakagawa M., Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:5547-5551.
80. Honda M., Kaneko S., Shimazaki T., Matsushita E., Kobayashi K., Ping L.H., Zhang H.C., Lemon S.M. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000, 31:1351-1359.
81. Hong Z., Beaudet-Miller M., Lanford R.E., Guerra B., Wright-Minogue J., Skelton A., Baroudy B.M., Reyes G.R., Lau J.Y. Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Virology 1999, 256:36-44.
82. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
83. Hope R.G., McLauchlan J. Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. J. Gen. Virol. 2000, 81:1913-1925.
84. Hope R.G., Murphy D.J., McLauchlan J. The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. J. Biol. Chem. 2002, 277:4261-4270.
85. Horie C., Iwahana H., Horie T., Shimizu I., Yoshimoto K., Yogita S., Tashiro S., Ito S., Itakura M. Detection of different quasispecies of hepatitis C virus core region in cancerous and noncancerous lesions. Biochem. Biophys. Res. Commun. 1996, 218:674-681.
86. Hourioux C., Patient R., Morin A., Blanchard E., Moreau A., Trassard S., Giraudeau B., Roingeard P. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007, 56:1302-1308.
87. Hu Z., Muroyama R., Kowatari N., Chang J., Omata M., Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci. 2009, 100:2465-2468.
88. Hui J.M., Kench J., Farrell G.C., Lin R., Samarasinghe D., Liddle C., Byth K., George J. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 2002, 17:873-881.
89. Hussy P., Langen H., Mous J., Jacobsen H. Hepatitis C virus core protein: carboxy-terminal boundaries of two processed species suggest cleavage by a signal peptide peptidase. Virology 1996, 224:93-104.
90. Idrees M., Rafique S., Rehman I., Akbar H., Yousaf M.Z., Butt S., Awan Z., Manzoor S., Akram M., Aftab M., Khubaib B., Riazuddin S. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J. Gastroenterol. 2009, 15:5080-5085.
91. Idrees M., Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect. Dis. 2008, 8:69.
92. Im S.S., Kwon S.K., Kim T.H., Kim H.I., Ahn Y.H. Regulation of glucose transporter type 4 isoform gene expression in muscle and adipocytes. IUBMB Life 2007, 59:134-145.
93. Ishii K., Shinohara M., Sawa M., Kogame M., Higami K., Sano M., Morita T., Sumino Y. Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino acid 70 in the core region. Intervirology 2010, 53:105-110.
94. it-Goughoulte M., Hourioux C., Patient R., Trassard S., Brand D., Roingeard P. Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly. J. Gen. Virol. 2006, 87:855-860.
95. Jackel-Cram C., Babiuk L.A., Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J. Hepatol. 2007, 46:999-1008.
96. Jackel-Cram C., Qiao L., Xiang Z., Brownlie R., Zhou Y., Babiuk L., Liu Q. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. J. Gen. Virol. 2010, 91:1388-1395.
97. Jhaveri R., McHutchison J., Patel K., Qiang G., Diehl A.M. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J. Infect. Dis. 2008, 197:283-291.
98. Jhaveri R., Qiang G., Diehl A.M. Domain 3 of hepatitis C virus core protein is sufficient for intracellular lipid accumulation. J. Infect. Dis. 2009, 200:1781-1788.
99. Jin D.Y., Wang H.L., Zhou Y., Chun A.C., Kibler K.V., Hou Y.D., Kung H., Jeang K.T. Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO J. 2000, 19:729-740.
100. Kao C.F., Chen S.Y., Chen J.Y., Wu Lee Y.H. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 2004, 23:2472-2483.
101. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999, 18:6867-6874.
102. Kato N., Yoshida H., Ono-Nita S.K., Kato J., Goto T., Otsuka M., Lan K., Matsushima K., Shiratori Y., Omata M. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000, 32:405-412.
103. Kim M., Ha Y., Park H.J. Structural requirements for assembly and homotypic interactions of the hepatitis C virus core protein. Virus Res. 2006, 122:137-143.
104. Kisseleva T., Bhattacharya S., Braunstein J., Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002, 285:1-24.
105. Klein K.C., Polyak S.J., Lingappa J.R. Unique features of hepatitis C virus capsid formation revealed by de novo cell-free assembly. J. Virol. 2004, 78:9257-9269.
106. Kobayashi M., Akuta N., Suzuki F., Hosaka T., Sezaki H., Kobayashi M., Suzuki Y., Arase Y., Ikeda K., Watahiki S., Mineta R., Iwasaki S., Miyakawa Y., Kumada H. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J. Med. Virol. 2010, 82:41-48.
107. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74:2046-2051.
108. Kunkel M., Watowich S.J. Conformational changes accompanying self-assembly of the hepatitis C virus core protein. Virology 2002, 294:239-245.
109. Lai M.S., Hsieh M.S., Chiu Y.H., Chen T.H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006, 43:1295-1302.
110. Lavie M., Goffard A., Dubuisson J. Assembly of a functional HCV glycoprotein heterodimer. Curr. Issues Mol. Biol. 2007, 9:71-86.
111. Lemberg M.K., Bland F.A., Weihofen A., Braud V.M., Martoglio B. Intramembrane proteolysis of signal peptides: an essential step in the generation of HLA-E epitopes. J. Immunol. 2001, 167:6441-6446.
112. Lemberg M.K., Martoglio B. Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. Mol. Cell 2002, 10:735-744.
113. Lemon S.M., Lerat H., Weinman S.A., Honda M. A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. Trans. Am. Clin. Climatol. Assoc. 2000, 111:146-156.
114. Lerat H., Honda M., Beard M.R., Loesch K., Sun J., Yang Y., Okuda M., Gosert R., Xiao S.Y., Weinman S.A., Lemon S.M. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122:352-365.
115. Lin W., Kim S.S., Yeung E., Kamegaya Y., Blackard J.T., Kim K.A., Holtzman M.J., Chung R.T. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J. Virol. 2006, 80:9226-9235.
116. Liu Q., Tackney C., Bhat R.A., Prince A.M., Zhang P. Regulated processing of hepatitis C virus core protein is linked to subcellular localization. J. Virol. 1997, 71:657-662.
117. Lo S.Y., Selby M.J., Ou J.H. Interaction between hepatitis C virus core protein and E1 envelope protein. J. Virol. 1996, 70:5177-5182.
118. Lohmann V., Roos A., Korner F., Koch J.O., Bartenschlager R. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J. Viral Hepat. 2000, 7:167-174.
119. Magnusson B., Asp L., Bostrom P., Ruiz M., Stillemark-Billton P., Linden D., Boren J., Olofsson S.O. Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1566-1571.
120. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
121. Masaki T., Suzuki R., Murakami K., Aizaki H., Ishii K., Murayama A., Date T., Matsuura Y., Miyamura T., Wakita T., Suzuki T. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol. 2008, 82:7964-7976.
122. Mason A.L., Lau J.Y., Hoang N., Qian K., Alexander G.J., Xu L., Guo L., Jacob S., Regenstein F.G., Zimmerman R., Everhart J.E., Wasserfall C., Maclaren N.K., Perrillo R.P. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 29:328-333.
123. Mathai J., Shimoda K., Banner B.F., Mori M., Bonkovsky H.L., Barnard G.F. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J. Interferon Cytokine Res. 1999, 19:1011-1018.
124. Matsumoto M., Hwang S.B., Jeng K.S., Zhu N., Lai M.M. Homotypic interaction and multimerization of hepatitis C virus core protein. Virology 1996, 218:43-51.
125. McHutchison J.G., Fried M.W. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 2003, 7:149-161.
126. McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J. Viral Hepat. 2000, 7:2-14.
127. McLauchlan J., Lemberg M.K., Hope G., Martoglio B. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J. 2002, 21:3980-3988.
128. Mehta S.H., Brancati F.L., Strathdee S.A., Pankow J.S., Netski D., Coresh J., Szklo M., Thomas D.L. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-56.
129. Melen K., Fagerlund R., Nyqvist M., Keskinen P., Julkunen I. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J. Med. Virol. 2004, 73:536-547.
130. Mihm S., Fayyazi A., Hartmann H., Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997, 25:735-739.
131. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., Bartenschlager R., Wakita T., Hijikata M., Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 2007, 9:1089-1097.
132. Mizukoshi E., Kaneko S., Yanagi M., Ohno H., Kaji K., Terasaki S., Shimoda A., Matsushita E., Kobayashi K. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J. Med. Virol. 1998, 56:217-223.
133. Moradpour D., Englert C., Wakita T., Wands J.R. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996, 222:51-63.
134. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5:453-463.
135. Moriishi K., Mochizuki R., Moriya K., Miyamoto H., Mori Y., Abe T., Murata S., Tanaka K., Miyamura T., Suzuki T., Koike K., Matsuura Y. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1661-1666.
136. Morita K., Tanaka K., Saito S., Kitamura T., Kiba T., Fujii T., Numata K., Sekihara H. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. J. Med. Virol. 1999, 58:359-365.
137. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., Matsuura Y., Kimura S., Miyamura T., Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 1998, 4:1065-1067.
138. Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Ishibashi K., Matsuura Y., Miyamura T., Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 1997, 78(Pt 7):1527-1531.
139. Moucari R., Asselah T., Cazals-Hatem D., Voitot H., Boyer N., Ripault M.P., Sobesky R., Martinot-Peignoux M., Maylin S., Nicolas-Chanoine M.H., Paradis V., Vidaud M., Valla D., Bedossa P., Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-423.
140. Mutoh M., Lung F.D., Long Y.Q., Roller P.P., Sikorski R.S., O'Connor P.M. A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 1999, 59:3480-3488.
141. Nagayama K., Kurosaki M., Enomoto N., Miyasaka Y., Marumo F., Sato C. Characteristics of hepatitis C viral genome associated with disease progression. Hepatology 2000, 31:745-750.
142. Nakai K., Okamoto T., Kimura-Someya T., Ishii K., Lim C.K., Tani H., Matsuo E., Abe T., Mori Y., Suzuki T., Miyamura T., Nunberg J.H., Moriishi K., Matsuura Y. Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein. J. Virol. 2006, 80:11265-11273.
143. Nakamoto S., Imazeki F., Fukai K., Fujiwara K., Arai M., Kanda T., Yonemitsu Y., Yokosuka O. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J. Hepatol. 2010, 52:72-78.
144. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
145. Nielsen N.H., Arnerlov C., Cajander S., Landberg G. Cyclin E expression and proliferation in breast cancer. Anal. Cell Pathol. 1998, 17:177-188.
146. Nolandt O., Kern V., Muller H., Pfaff E., Theilmann L., Welker R., Krausslich H.G. Analysis of hepatitis C virus core protein interaction domains. J. Gen. Virol. 1997, 78(Pt 6):1331-1340.
147. Novick D., Cohen B., Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 1994, 77:391-400.
148. Nunez O., Fernandez-Martinez A., Majano P.L., Apolinario A., Gomez-Gonzalo M., Benedicto I., Lopez-Cabrera M., Bosca L., Clemente G., Garcia-Monzon C., Martin-Sanz P. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53:1665-1672.
149. Ogata S., Nagano-Fujii M., Ku Y., Yoon S., Hotta H. Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J. Clin. Microbiol. 2002, 40:3625-3630.
150. Ogino T., Fukuda H., Imajoh-Ohmi S., Kohara M., Nomoto A. Membrane binding properties and terminal residues of the mature hepatitis C virus capsid protein in insect cells. J. Virol. 2004, 78:11766-11777.
151. Ogura S., Akuta N., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Hosaka T., Kobayashi M., Suzuki F., Suzuki Y., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Kumada H. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. Intervirology 2009, 52:179-188.
152. Okamoto K., Mori Y., Komoda Y., Okamoto T., Okochi M., Takeda M., Suzuki T., Moriishi K., Matsuura Y. Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation. J. Virol. 2008, 82:8349-8361.
153. Okamoto K., Moriishi K., Miyamura T., Matsuura Y. Intramembrane proteolysis and endoplasmic reticulum retention of hepatitis C virus core protein. J. Virol. 2004, 78:6370-6380.
154. Okanoue T., Itoh Y., Hashimoto H., Yasui K., Minami M., Takehara T., Tanaka E., Onji M., Toyota J., Chayama K., Yoshioka K., Izumi N., Akuta N., Kumada H. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J. Gastroenterol. 2009, 44:952-963.
155. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., Weinman S.A. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375.
156. Otsuka M., Kato N., Lan K., Yoshida H., Kato J., Goto T., Shiratori Y., Omata M. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J. Biol. Chem. 2000, 275:34122-34130.
157. Patton H.M., Patel K., Behling C., Bylund D., Blatt L.M., Vallee M., Heaton S., Conrad A., Pockros P.J., McHutchison J.G. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 2004, 40:484-490.
158. Pavlovic D., Neville D.C., Argaud O., Blumberg B., Dwek R.A., Fischer W.B., Zitzmann N. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6104-6108.
159. Pazienza V., Clement S., Pugnale P., Conzelman S., Foti M., Mangia A., Negro F. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007, 45:1164-1171.
160. Pazienza V., Vinciguerra M., Andriulli A., Mangia A. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J. Gen. Virol. 2010, 91:1678-1686.
161. Pene V., Hernandez C., Vauloup-Fellous C., Garaud-Aunis J., Rosenberg A.R. Sequential processing of hepatitis C virus core protein by host cell signal peptidase and signal peptide peptidase: a reassessment. J. Viral Hepat. 2009, 16:705-715.
162. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
163. Perez-Berna A.J., Veiga A.S., Castanho M.A., Villalain J. Hepatitis C virus core protein binding to lipid membranes: the role of domains 1 and 2. J. Viral Hepat. 2008, 15:346-356.
164. Perlemuter G., Sabile A., Letteron P., Vona G., Topilco A., Chretien Y., Koike K., Pessayre D., Chapman J., Barba G., Brechot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002, 16:185-194.
165. Petrides A.S., Vogt C., Schulze-Berge D., Matthews D., Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994, 19:616-627.
166. Petta S., Camma C., Di Marco V., Alessi N., Cabibi D., Caldarella R., Licata A., Massenti F., Tarantino G., Marchesini G., Craxi A. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am. J. Gastroenterol. 2008, 103:1136-1144.
167. Piodi A., Chouteau P., Lerat H., Hezode C., Pawlotsky J.M. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 2008, 48:16-27.
168. Ramalho F. Hepatitis C virus infection and liver steatosis. Antiviral Res. 2003, 60:125-127.
169. Ray R.B., Lagging L.M., Meyer K., Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 1996, 70:4438-4443.
170. Ray R.B., Meyer K., Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996, 226:176-182.
171. Ray R.B., Steele R., Meyer K., Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J. Biol. Chem. 1997, 272:10983-10986.
172. Reed K.E., Rice C.M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 2000, 242:55-84.
173. Roingeard P., Hourioux C. Hepatitis C virus core protein, lipid droplets and steatosis. J. Viral Hepat. 2008, 15:157-164.
174. Rouille Y., Helle F., Delgrange D., Roingeard P., Voisset C., Blanchard E., Belouzard S., McKeating J., Patel A.H., Maertens G., Wakita T., Wychowski C., Dubuisson J. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J. Virol. 2006, 80:2832-2841.
175. Rubbia-Brandt L., Leandro G., Spahr L., Giostra E., Quadri R., Male P.J., Negro F. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001, 39:119-124.
176. Rubbia-Brandt L., Quadri R., Abid et al., 2005 K., Giostra E., Male P.J., Mentha G., Spahr L., Zarski J.P., Borisch B., Hadengue A., Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 2000, 33:106-115.
177. Ruggieri A., Harada T., Matsuura Y., Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997, 229:68-76.
178. Ruster B., Zeuzem S., Krump-Konvalinkova V., Berg T., Jonas S., Severin K., Roth W.K. Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. J. Med. Virol. 2001, 63:128-134.
179. Sakamoto M., Akahane Y., Tsuda F., Tanaka T., Woodfield D.G., Okamoto H. Entire nucleotide sequence and characterization of a hepatitis C virus of genotype V/3a. J. Gen. Virol. 1994, 75(Pt 7):1761-1768.
180. Sato S., Fukasawa M., Yamakawa Y., Natsume T., Suzuki T., Shoji I., Aizaki H., Miyamura T., Nishijima M. Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J. Biochem. 2006, 139:921-930.
181. Sato Y., Kato J., Takimoto R., Takada K., Kawano Y., Miyanishi K., Kobune M., Sato Y., Takayama T., Matunaga T., Niitsu Y. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut 2006, 55:1801-1808.
182. Serfaty L., Poujol-Robert A., Carbonell N., Chazouilleres O., Poupon R.E., Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am. J. Gastroenterol. 2002, 97:1807-1812.
183. Shavinskaya A., Boulant S., Penin F., McLauchlan J., Bartenschlager R. The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. J. Biol. Chem. 2007, 282:37158-37169.
184. Sheridan I., Pybus O.G., Holmes E.C., Klenerman P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J. Virol. 2004, 78:3447-3454.
185. Shimizu Y.K., Feinstone S.M., Kohara M., Purcell R.H., Yoshikura H. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 1996, 23:205-209.
186. Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Tsukamoto K., Kimura S., Moriya K., Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-848.
187. Shrivastava A., Manna S.K., Ray R., Aggarwal B.B. Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J. Virol. 1998, 72:9722-9728.
188. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 2004, 85:3173-3188.
189. Simmonds P., Smith D.B., McOmish F., Yap P.L., Kolberg J., Urdea M.S., Holmes E.C. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J. Gen. Virol. 1994, 75(Pt 5):1053-1061.
190. Spruck C.H., Won K.A., Reed S.I. Deregulated cyclin E induces chromosome instability. Nature 1999, 401:297-300.
191. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
192. Suzuki R., Matsuura Y., Suzuki T., Ando A., Chiba J., Harada S., Saito I., Miyamura T. Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted. J. Gen. Virol. 1995, 76(Pt 1):53-61.
193. Suzuki R., Sakamoto S., Tsutsumi T., Rikimaru A., Tanaka K., Shimoike T., Moriishi K., Iwasaki T., Mizumoto K., Matsuura Y., Miyamura T., Suzuki T. Molecular determinants for subcellular localization of hepatitis C virus core protein. J. Virol. 2005, 79:1271-1281.
194. Tachi Y., Katano Y., Honda T., Hayashi K., Ishigami M., Itoh A., Hirooka Y., Nakano I., Samejima Y., Goto H. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int. 2010, 30:554-559.
195. Tai D.I., Tsai S.L., Chen Y.M., Chuang Y.L., Peng C.Y., Sheen I.S., Yeh C.T., Chang K.S., Huang S.N., Kuo G.C., Liaw Y.F. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000, 31:656-664.
196. Takahashi K., Iwata K., Matsumoto M., Matsumoto H., Nakao K., Hatahara T., Ohta Y., Kanai K., Maruo H., Baba K., Hijikata M., Mishiro S. Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited. Hepatol. Res. 2001, 20:161-171.
197. Takahashi K., Kishimoto S., Yoshizawa H., Okamoto H., Yoshikawa A., Mishiro S. p26 protein and 33-nm particle associated with nucleocapsid of hepatitis C virus recovered from the circulation of infected hosts. Virology 1992, 191:431-434.
198. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
199. Tang X., Wagoner J., Negash A., Austin M., McLauchlan J., Hahn Y.S., Rosen H.R., Polyak S.J. Functional characterization of core genes from patients with acute hepatitis C virus infection. J. Infect. Dis. 2010, 201:912-922.
200. Targett-Adams P., Boulant S., McLauchlan J. Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. J. Virol. 2008, 82:2182-2195.
201. Targett-Adams P., Hope G., Boulant S., McLauchlan J. Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production. J. Biol. Chem. 2008, 283:16850-16859.
202. Tellinghuisen T.L., Rice C.M. Interaction between hepatitis C virus proteins and host cell factors. Curr. Opin. Microbiol. 2002, 5:419-427.
203. Ten Hoeve J., de Jesus Ibarra-Sanchez M., Fu Y., Zhu W., Tremblay M., David M., Shuai K. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell Biol. 2002, 22:5662-5668.
204. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
205. Timm J., Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 2007, 13:4808-4817.
206. Toyoda H., Kumada T., Kiriyama S., Tanikawa M., Hisanaga Y., Kanamori A., Tada T., Arakawa T., Fujimori M., Niinomi T., Ando N., Yasuda S., Sakai K., Kimura J. High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. J. Gastroenterol. 2010, [Epub ahead of print].
207. Tsukiyama-Kohara K., Iizuka N., Kohara M., Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 1992, 66:1476-1483.
208. Tsutsumi T., Suzuki T., Shimoike T., Suzuki R., Moriya K., Shintani Y., Fujie H., Matsuura Y., Koike K., Miyamura T. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002, 35:937-946.
209. Veldt B.J., Chen W., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., de Knegt R.J., Zeuzem S., Manns M.P., Hansen B.E., Schalm S.W., Janssen H.L. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
210. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
211. Walewski J.L., Gutierrez J.A., Branch-Elliman W., Stump D.D., Keller T.R., Rodriguez A., Benson G., Branch A.D. Mutation master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. RNA 2002, 8:557-571.
212. Wang C., Sarnow P., Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J. Virol. 1993, 67:3338-3344.
213. Wang F., Yoshida I., Takamatsu M., Ishido S., Fujita T., Oka K., Hotta H. Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1. Biochem. Biophys. Res. Commun. 2000, 273:479-484.
214. Watashi K., Hijikata M., Marusawa H., Doi T., Shimotohno K. Cytoplasmic localization is important for transcription factor nuclear factor-kappa B activation by hepatitis C virus core protein through its amino terminal region. Virology 2001, 286:391-402.
215. Wiggins D., Gibbons G.F. Origin of hepatic very-low-density lipoprotein triacylglycerol: the contribution of cellular phospholipid. Biochem. J. 1996, 320(Pt 2):673-679.
216. Yamaguchi Y., Hino K., Fujiwara D., Ren F., Katoh Y., Satoh Y., Okita K. Expression of type I interferon receptor in liver and peripheral blood mononuclear cells in chronic hepatitis C patients. Dig. Dis. Sci. 2002, 47:1611-1617.
217. Yan B.S., Tam M.H., Syu W.J. Self-association of the C-terminal domain of the hepatitis-C virus core protein. Eur. J. Biochem. 1998, 258:100-106.
218. Yan X.B., Chen Z., Luo D.H., Xu X.Y., Wu W., Zhou L.F. Proapoptotic and pronecrosis effect of different truncated hepatitis C virus core proteins. J. Zhejiang Univ. Sci. B 2005, 6:295-300.
219. Yao Z.Q., Eisen-Vandervelde A., Waggoner S.N., Cale E.M., Hahn Y.S. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J. Virol. 2004, 78:6409-6419.
220. Yasui K., Wakita T., Tsukiyama-Kohara K., Funahashi S.I., Ichikawa M., Kajita T., Moradpour D., Wands J.R., Kohara M. The native form and maturation process of hepatitis C virus core protein. J. Virol. 1998, 72:6048-6055.
221. Yatsuhashi H., Fujino T., Matsumoto T., Inoue O., Koga M., Yano M. Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J. Hepatol. 1999, 30:995-1003.
222. Yoshida H., Kato N., Shiratori Y., Otsuka M., Maeda S., Kato J., Omata M. Hepatitis C virus core protein activates nuclear factor kappa B-dependent signaling through tumor necrosis factor receptor-associated factor. J. Biol. Chem. 2001, 276:16399-16405.
223. Zein C.O., Levy C., Basu A., Zein N.N. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am. J. Gastroenterol. 2005, 100:48-55.